CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate
Journal of Clinical and Experimental Hematopathology · 2026 · 66 (1) · 27-36
DOI: 10.3960/jslrt.25087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2026. Verfasst von Keisuke Sawada und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Methotrexate, Lymphoma, Large B-Cell, Diffuse, Arthritis, Rheumatoid, Biomarkers, Tumor. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Department of Oral Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
- Department of Diagnostic Pathology, Saitama Red Cross Hospital, Saitama, Japan.
- Department of Hematology, Shinmatsudo Central General Hospital, Chiba, Japan.
- Department of Hematology, Saitama Medical Center Saitama Medical University, Saitama, Japan.
Zitieren
APA
Sawada, K., Takahashi, T., Fukumura, Y., Onagi, H., Ashizawa, K., Yamashita, T., Yamamoto, W., Takayanagi, N., Adachi, A., Kashimura, M., Tabayashi, T., Tamaru, J. I., Higashi, M., & Momose, S. (2026). CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate. Journal of Clinical and Experimental Hematopathology, 66(1), 27-36. https://doi.org/10.3960/jslrt.25087
Vancouver
Sawada K, Takahashi T, Fukumura Y, Onagi H, Ashizawa K, Yamashita T, et al. CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate. Journal of Clinical and Experimental Hematopathology. 2026;66(1):27-36. doi:10.3960/jslrt.25087
BibTeX
@article{Sawada2026,
author = {Sawada, Keisuke and Takahashi, Takumi and Fukumura, Yuki and Onagi, Hiroko and Ashizawa, Karin and Yamashita, Takahisa and Yamamoto, Wataru and Takayanagi, Natsuko and Adachi, Akiko and Kashimura, Makoto and Tabayashi, Takayuki and Tamaru, Jun-Ichi and Higashi, Morihiro and Momose, Shuji},
title = {CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2026},
volume = {66},
number = {1},
pages = {27--36},
doi = {10.3960/jslrt.25087}
}
EUVIMED